Analysis of electrocardiographic data following use of paroxetine in pediatric depression and obsessive-compulsive disorder

Stan Krulewicz, David J. Carpenter, Regan Fong, Joseph P. Horrigan, Alan Lipschitz, Philip Perera, Karen Wagner

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: This retrospective analysis of electrocardiographic (ECG) data investigated the cardiovascular effects of paroxetine 10-50 mg/day in pediatric patients (7-18 years of age). Data were collected from three 8- to 10-week, randomized, placebo-controlled, double-blind trials of paroxetine in pediatric patients with major depressive disorder or obsessive-compulsive disorder. Method: Electrocardiograms (ECGs) were retrospectively retrieved from 63 study sites in the United States and Canada. Only patients with at least one screening and one on-treatment ECG were included. ECGs were analyzed for heart rate, QT interval corrected using Bazett's formula (QTcB) and Fridericia's formula (QTcF), at screening and while being treated. PR, R-R, and QRS intervals and the maximum change in QTcB and QTcF from screening to endpoint were determined. Clinically significant thresholds were defined a priori. Results: A total of 1,451 ECGs from 449 patients receiving placebo (n = 207), paroxetine (n = 200), or imipramine (n = 42) were analyzed. Treatment with paroxetine did not significantly increase QTcB or QTcF or any ECG parameters compared with placebo. Treatment with imipramine significantly increased heart rate and QTcB, R-R, and QRS intervals compared with either paroxetine or placebo. Conclusions: Data from this retrospective study indicate that paroxetine (10-50 mg/day) is unlikely to be associated with significant ECG changes in medically healthy pediatric patients.

Original languageEnglish (US)
Pages (from-to)422-430
Number of pages9
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume45
Issue number4
DOIs
StatePublished - Apr 2006

Fingerprint

Paroxetine
Obsessive-Compulsive Disorder
Depression
Pediatrics
Placebos
Electrocardiography
Imipramine
Heart Rate
Major Depressive Disorder
Canada
Therapeutics
Retrospective Studies

Keywords

  • Electrocardiogram
  • Major depressive disorder
  • Obsessive-compulsive disorder
  • Paroxetine
  • Pediatric

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Analysis of electrocardiographic data following use of paroxetine in pediatric depression and obsessive-compulsive disorder. / Krulewicz, Stan; Carpenter, David J.; Fong, Regan; Horrigan, Joseph P.; Lipschitz, Alan; Perera, Philip; Wagner, Karen.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 45, No. 4, 04.2006, p. 422-430.

Research output: Contribution to journalArticle

Krulewicz, Stan ; Carpenter, David J. ; Fong, Regan ; Horrigan, Joseph P. ; Lipschitz, Alan ; Perera, Philip ; Wagner, Karen. / Analysis of electrocardiographic data following use of paroxetine in pediatric depression and obsessive-compulsive disorder. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2006 ; Vol. 45, No. 4. pp. 422-430.
@article{23449a65136f40adaccdad471c90eb92,
title = "Analysis of electrocardiographic data following use of paroxetine in pediatric depression and obsessive-compulsive disorder",
abstract = "Objective: This retrospective analysis of electrocardiographic (ECG) data investigated the cardiovascular effects of paroxetine 10-50 mg/day in pediatric patients (7-18 years of age). Data were collected from three 8- to 10-week, randomized, placebo-controlled, double-blind trials of paroxetine in pediatric patients with major depressive disorder or obsessive-compulsive disorder. Method: Electrocardiograms (ECGs) were retrospectively retrieved from 63 study sites in the United States and Canada. Only patients with at least one screening and one on-treatment ECG were included. ECGs were analyzed for heart rate, QT interval corrected using Bazett's formula (QTcB) and Fridericia's formula (QTcF), at screening and while being treated. PR, R-R, and QRS intervals and the maximum change in QTcB and QTcF from screening to endpoint were determined. Clinically significant thresholds were defined a priori. Results: A total of 1,451 ECGs from 449 patients receiving placebo (n = 207), paroxetine (n = 200), or imipramine (n = 42) were analyzed. Treatment with paroxetine did not significantly increase QTcB or QTcF or any ECG parameters compared with placebo. Treatment with imipramine significantly increased heart rate and QTcB, R-R, and QRS intervals compared with either paroxetine or placebo. Conclusions: Data from this retrospective study indicate that paroxetine (10-50 mg/day) is unlikely to be associated with significant ECG changes in medically healthy pediatric patients.",
keywords = "Electrocardiogram, Major depressive disorder, Obsessive-compulsive disorder, Paroxetine, Pediatric",
author = "Stan Krulewicz and Carpenter, {David J.} and Regan Fong and Horrigan, {Joseph P.} and Alan Lipschitz and Philip Perera and Karen Wagner",
year = "2006",
month = "4",
doi = "10.1097/01.chi.0000198593.30702.48",
language = "English (US)",
volume = "45",
pages = "422--430",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Analysis of electrocardiographic data following use of paroxetine in pediatric depression and obsessive-compulsive disorder

AU - Krulewicz, Stan

AU - Carpenter, David J.

AU - Fong, Regan

AU - Horrigan, Joseph P.

AU - Lipschitz, Alan

AU - Perera, Philip

AU - Wagner, Karen

PY - 2006/4

Y1 - 2006/4

N2 - Objective: This retrospective analysis of electrocardiographic (ECG) data investigated the cardiovascular effects of paroxetine 10-50 mg/day in pediatric patients (7-18 years of age). Data were collected from three 8- to 10-week, randomized, placebo-controlled, double-blind trials of paroxetine in pediatric patients with major depressive disorder or obsessive-compulsive disorder. Method: Electrocardiograms (ECGs) were retrospectively retrieved from 63 study sites in the United States and Canada. Only patients with at least one screening and one on-treatment ECG were included. ECGs were analyzed for heart rate, QT interval corrected using Bazett's formula (QTcB) and Fridericia's formula (QTcF), at screening and while being treated. PR, R-R, and QRS intervals and the maximum change in QTcB and QTcF from screening to endpoint were determined. Clinically significant thresholds were defined a priori. Results: A total of 1,451 ECGs from 449 patients receiving placebo (n = 207), paroxetine (n = 200), or imipramine (n = 42) were analyzed. Treatment with paroxetine did not significantly increase QTcB or QTcF or any ECG parameters compared with placebo. Treatment with imipramine significantly increased heart rate and QTcB, R-R, and QRS intervals compared with either paroxetine or placebo. Conclusions: Data from this retrospective study indicate that paroxetine (10-50 mg/day) is unlikely to be associated with significant ECG changes in medically healthy pediatric patients.

AB - Objective: This retrospective analysis of electrocardiographic (ECG) data investigated the cardiovascular effects of paroxetine 10-50 mg/day in pediatric patients (7-18 years of age). Data were collected from three 8- to 10-week, randomized, placebo-controlled, double-blind trials of paroxetine in pediatric patients with major depressive disorder or obsessive-compulsive disorder. Method: Electrocardiograms (ECGs) were retrospectively retrieved from 63 study sites in the United States and Canada. Only patients with at least one screening and one on-treatment ECG were included. ECGs were analyzed for heart rate, QT interval corrected using Bazett's formula (QTcB) and Fridericia's formula (QTcF), at screening and while being treated. PR, R-R, and QRS intervals and the maximum change in QTcB and QTcF from screening to endpoint were determined. Clinically significant thresholds were defined a priori. Results: A total of 1,451 ECGs from 449 patients receiving placebo (n = 207), paroxetine (n = 200), or imipramine (n = 42) were analyzed. Treatment with paroxetine did not significantly increase QTcB or QTcF or any ECG parameters compared with placebo. Treatment with imipramine significantly increased heart rate and QTcB, R-R, and QRS intervals compared with either paroxetine or placebo. Conclusions: Data from this retrospective study indicate that paroxetine (10-50 mg/day) is unlikely to be associated with significant ECG changes in medically healthy pediatric patients.

KW - Electrocardiogram

KW - Major depressive disorder

KW - Obsessive-compulsive disorder

KW - Paroxetine

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=33646337660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646337660&partnerID=8YFLogxK

U2 - 10.1097/01.chi.0000198593.30702.48

DO - 10.1097/01.chi.0000198593.30702.48

M3 - Article

C2 - 16601647

AN - SCOPUS:33646337660

VL - 45

SP - 422

EP - 430

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 4

ER -